

Table 2 Measured values of variables

	Group	Baseline	T0	T1	T2	T3	T5	T7	T10
RR (ms)	Sugammadex	889 ± 106	889 ± 107	896 ± 115	883 ± 129	872 ± 137	875 ± 128	869 ± 131	849 ± 151
	Neostigmine	884 ± 122	870 ± 121	763 ± 125*	795 ± 116	841 ± 118	907 ± 121	907 ± 138	915 ± 150
MAP (mmHg)	Sugammadex	71 ± 11	72 ± 11	72 ± 10	70 ± 9	73 ± 10	75 ± 11	74 ± 10	76 ± 12
	Neostigmine	71 ± 11	72 ± 11	73 ± 11	72 ± 10	74 ± 11	76 ± 11	76 ± 10	79 ± 12
BIS	Sugammadex	42 ± 7	41 ± 8	40 ± 8	41 ± 9	42 ± 10	41 ± 8	42 ± 7	43 ± 10
	Neostigmine	41 ± 13	41 ± 15	39 ± 12	42 ± 13	42 ± 10	42 ± 13	43 ± 16	44 ± 9

Data are presented as mean ± standard deviation. * $p < 0.05$ versus sugammadex group. *T0*: reversal of neuromuscular blockade, *T1–T10*: 1–10 min after reversal, *RR*: RR interval, *MAP*: mean arterial pressure, *BIS*: bispectral index